Hester Biosciences Limited - Asset Resilience Ratio
Hester Biosciences Limited (HESTERBIO) has an Asset Resilience Ratio of 4.41% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Hester Biosciences Limited's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Hester Biosciences Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Hester Biosciences Limited.
Liquid Assets Composition Over Time
This chart breaks down Hester Biosciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Hester Biosciences Limited to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs79.38 Million | 1.18% |
| Short-term Investments | Rs218.68 Million | 3.24% |
| Total Liquid Assets | Rs298.06 Million | 4.41% |
Asset Resilience Insights
- Limited Liquidity: Hester Biosciences Limited maintains only 4.41% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hester Biosciences Limited Industry Peers by Asset Resilience Ratio
Compare Hester Biosciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Hester Biosciences Limited (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Hester Biosciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.19% | Rs12.54 Million ≈ $135.62K |
Rs6.53 Billion ≈ $70.66 Million |
-0.19pp |
| 2024-03-31 | 0.39% | Rs25.56 Million ≈ $276.42K |
Rs6.62 Billion ≈ $71.63 Million |
-2.97pp |
| 2023-03-31 | 3.35% | Rs183.07 Million ≈ $1.98 Million |
Rs5.46 Billion ≈ $59.03 Million |
+3.27pp |
| 2022-03-31 | 0.08% | Rs4.53 Million ≈ $48.99K |
Rs5.62 Billion ≈ $60.80 Million |
+0.01pp |
| 2021-03-31 | 0.07% | Rs2.93 Million ≈ $31.69K |
Rs4.11 Billion ≈ $44.45 Million |
-6.05pp |
| 2020-03-31 | 6.12% | Rs235.31 Million ≈ $2.54 Million |
Rs3.84 Billion ≈ $41.58 Million |
-7.11pp |
| 2019-03-31 | 13.23% | Rs396.25 Million ≈ $4.29 Million |
Rs2.99 Billion ≈ $32.38 Million |
+11.70pp |
| 2018-03-31 | 1.54% | Rs37.51 Million ≈ $405.61K |
Rs2.44 Billion ≈ $26.39 Million |
+1.51pp |
| 2017-03-31 | 0.02% | Rs478.82K ≈ $5.18K |
Rs2.18 Billion ≈ $23.59 Million |
+0.31pp |
| 2016-03-31 | -0.29% | Rs-5.26 Million ≈ $-56.89K |
Rs1.84 Billion ≈ $19.93 Million |
-- |
About Hester Biosciences Limited
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates through the Poultry Healthcare and Animal Healthcare segments. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl… Read more